PURPOSE: To
determine if adjunctive use of mitomycin C (MMC) would increase the success
rate of non-penetrating deep sclerectomy(NPDS). METHODS: Prospective trail of
26 eyes of 26 patients underwent NPDS either with (13 eyes/13 patients) or
without (13 eyes/13 patients) MMC. Success was defined as IOP ≤ 21 mmHg
with/without medications and a ≥ 30% reduction in the IOP and without
reoperation. RESULTS: At 2 years the success rate of the MMC group (76.9%) was
significantly higher (p < 0.001) than the control (61.5%). Mean
postoperative IOP was lower for the MMC group (15.8±5.6 mmHg) than for control
(17.8±2.8 mmHg). Complications included hyphema (2 patients in the MMC group
and 1 in the control group) and suprachoroidal hemorrhage (developed in 1
patient in the MMC group and 1 patient in the control group). At the last
follow-up, none of the patients in either group experienced visual acuity
deterioration ≤ 2 lines on the Snellen chart. CONCLUSIONS: The increased
success of the glaucoma procedure in the mytomicin group together with
relatively minor toxicity suggests its use is beneficial in primary
nonpenetrating deep sclerectomy..
CR: None